SPONSOR
Peking University People's Hospital
Total Trials
8
Recruiting
8
Phases
Phase 1, Phase 2, Phase 2
Conditions studied: Gastrointestinal Stromal Tumor of StomachSubmucosal Tumor of StomachOsteosarcomaOsteosarcoma MetastaticIdiopathic Inflammatory Myopathies (IIMs)Relapsed Adult ALLB-cell Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaRelapsed Pediatric ALLAcute Myeloid Leukemia (AML)
Peking University People's Hospital is a clinical research sponsor with 8 registered studies on ClinicalTrials.gov, of which 8 are actively recruiting participants. Research covers conditions including Gastrointestinal Stromal Tumor of Stomach, Submucosal Tumor of Stomach, Osteosarcoma, Osteosarcoma Metastatic.
The trial portfolio spans Phase 1, Phase 2, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Peking University People's Hospital
How many clinical trials has Peking University People's Hospital sponsored?
ClinicalMetric currently tracks 8 clinical trials sponsored by Peking University People's Hospital, of which 8 are actively recruiting participants. These trials cover conditions including Gastrointestinal Stromal Tumor of Stomach, Submucosal Tumor of Stomach, Osteosarcoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Peking University People's Hospital research focus on?
Peking University People's Hospital clinical trials span Gastrointestinal Stromal Tumor of Stomach, Submucosal Tumor of Stomach, Osteosarcoma, Osteosarcoma Metastatic, Idiopathic Inflammatory Myopathies (IIMs), and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Peking University People's Hospital clinical trial?
To participate in a Peking University People's Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Peking University People's Hospital trials with current recruitment status updated daily.
Clinical Trials by Peking University People's Hospital
NCT06748690
Recruiting
MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
Gastrointestinal Stromal Tumor of Stomach
NCT07479732 Phase 1, Phase 2
Recruiting
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Osteosarcoma
NCT07564271
Recruiting
Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies
Idiopathic Inflammatory Myopathies (IIMs)
NCT06581081
Recruiting
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
Relapsed Adult ALL
NCT07500441
Recruiting
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Acute Myeloid Leukemia (AML)
NCT06778603 Phase 1, Phase 2
Recruiting
B7-H3 NIR Imaging for Osteosarcoma Surgery
Osteosarcoma
NCT07484087
Recruiting
Ablation Compare With Surgery for Early Breast Cancer
Breast Cancer
NCT06984536 Phase 2
Recruiting
Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT
Myelodysplastic Syndrome
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology